Ocular Therapeutix, Inc.
NASDAQ:OCULBiotechnology
-$0.11 today
- Market cap
- $1.31B
- Beta
- 0.90
- P/E (TTM)
- -7.3
- EPS (TTM)
- -$1.30
Volume 3.67M
Average 3.00M
OCUL Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Ocular Therapeutix, Inc.NASDAQ: OCUL
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $36.58M rose 20.0% year over year, ahead of the +14.7% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 19.5% from the prior quarter. Over 3 fiscal years it compounded at +17.9% a year.
Context
- Selling, general & admin amounted to 228.3% of revenue in FY2025, up 67.8 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 9 analysts of $82.68M (-30.1%) for the fiscal year ending Dec 2026, a slowdown from the +15.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $36.58M+19.5% QoQ
- Last fiscal yearDec 2025
- $118.3M+15.7% YoY
- LTMMar 2026
- $124.38M+14.7% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 118.3M USD
- Year-over-year change
- +15.7%
- 4-year CAGR
- +15.2%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 118.3M | +15.7% |
| FY2024 | 2024-12-31 | 102.24M | +37.3% |
| FY2023 | 2023-12-31 | 74.49M | +3.2% |
| FY2022 | 2022-12-31 | 72.15M | +7.6% |
| FY2021 | 2021-12-31 | 67.07M | — |
Selling, General & Admin vs competitors
How OCUL compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +14.7% is the 3rd highest of 9, against a peer median of +1.6%.
- Selling, general & admin amounts to 239.0% of revenue for OCUL, versus a peer median of 359.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $2.22B USD | +1.8% | +14.8% | 41.8% | |
| LTM Jun 2026 | $386.7M USD | +34.7% | +19.5% | 63.1% | |
| LTM Apr 2026 | $177.31M USD | -11.1% | +9.5% | 61.1% | |
| LTM Mar 2026 | $124.38M USD | +14.7% | +17.9% | 239.0% | |
| LTM Mar 2026 | $86.54M USD | — | — | 32.2% | |
| LTM Mar 2026 | $53.04M USD | +1.3% | -5.0% | 696.5% | |
| LTM Sep 2026 | $42.74M USD | -6.8% | -6.1% | — | |
| LTM Mar 2026 | $38.12M USD | -1.4% | +24.4% | 11443.7% | |
| LTM Mar 2026 | $29.24M USD | +9.4% | -8.0% | 654.9% | |
| LTM Mar 2026 | CHF 27.55M CHF | +39.2% | +54.0% | 5466.6% | |
SGPSpyGlass Pharma, Inc. Common Stock | FY2025 | $12.2M USD | — | — | — |
| Peer median (excluding OCUL) | — | +1.6% | +12.1% | 359.0% | |
Competitors are the stored peer set for OCUL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 43.52M | 51.49M | 58.44M | 63.72M | 51.82M |
| Cost of Revenue | 4.41M | 4.54M | 5.28M | 5.63M | 6.57M |
| Gross Profit | 39.12M | 46.95M | 53.16M | 58.1M | 45.25M |
| Gross Margin | 89.9% | 91.2% | 91.0% | 91.2% | 87.3% |
| Research & Development | 50.08M | 53.46M | 61.06M | 127.64M | 197.1M |
| Selling, General & Admin | 67.07M | 72.15M | 74.49M | 102.24M | 118.3M |
| Operating Expenses | 117.15M | 125.61M | 135.54M | 229.88M | 315.39M |
| Depreciation & Amortization | 2.42M | 2.11M | 2.98M | 3.79M | 4.32M |
| EBITDA | 2.54M | (61.91M) | (66.42M) | (176.14M) | (249.78M) |
| EBITDA Margin | 5.8% | -120.2% | -113.6% | -276.4% | -482.0% |
| Operating Income | (78.04M) | (78.65M) | (82.38M) | (171.78M) | (270.02M) |
| Operating Margin | -179.3% | -152.7% | -141.0% | -269.6% | -521.0% |
| Interest Income | 33K | 798K | 3.98M | 20.28M | 18.36M |
| Interest Expense | 6.67M | 7.02M | 11.34M | 13.58M | 11.84M |
| Other Income / Expenses | 71.48M | 7.62M | 1.65M | (21.73M) | 4.08M |
| Income Before Tax | (6.55M) | (71.04M) | (80.74M) | (193.51M) | (265.94M) |
| Pre-Tax Margin | -15.1% | -138.0% | -138.1% | -303.7% | -513.2% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (6.55M) | (71.04M) | (80.74M) | (193.51M) | (265.94M) |
| Net Margin | -15.1% | -138.0% | -138.1% | -303.7% | -513.2% |
| EPS (Basic) | (1.05) | (1.04) | (1.09) | (1.22) | (1.42) |
| EPS (Diluted) | (0.98) | (0.97) | (1.02) | (1.22) | (1.42) |
| Weighted Avg Shares | 76.39M | 76.88M | 79.83M | 158.27M | 187.24M |
| Weighted Avg Shares (Diluted) | 82.16M | 82.64M | 85.6M | 158.27M | 187.24M |
Ocular Therapeutix, Inc.
NASDAQ:OCUL
Intrinsic Alpha fair value
Locked
Current Price
$5.94
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.